Anondita Medicare IPO
Anondita Medicare Limited · Healthcare Products
- Issue price
- ₹145per share
- Issue size
- ₹69.5 Cr47,93,000 shares
- Face value
- ₹10per equity share
- Lot size
- 1,000 sharesMin. ₹1.45 L at the upper price
- Anchor biddingThu, 2025
- OpensFri, 2025
- ClosesTue, 2025
- AllotmentThu, 2025
- ListingMon, 2025
Dates marked in the offer document as tentative. Times in IST.
Information only, not investment advice. This page provides information compiled from official offer documents for information purposes only. It is not investment advice or a recommendation to apply for, buy or sell any security. We are not a SEBI-registered investment adviser or research analyst. Investments in IPOs are subject to market risks; read the offer document carefully before investing.
Issue details
- Issue type
- Book built, fresh issue
- Fresh issue
- 47,93,000 shares (₹69.5 Cr)
- Offer for sale
- None
- Total issue
- 47,93,000 shares (₹69.5 Cr)
- Market maker portion
- 2,70,000 shares
- Face value
- ₹10
- Listing at
- NSE Emerge
- Promoter holding
- 83.95% → 61.71%
Source: ProspectusUpdated
Reservation
Share of the total issue- Retail38.6%
- Anchor32.8%
- QIB ex-anchor22.0%
- Market maker6.6%
| Category | Shares | Of net offer | Stated in RHP |
|---|---|---|---|
| Retail individual investors | 15,86,000 | 41.28% | 35% |
| Non-institutional investors (NII) | — | — | 15% |
| Qualified institutional buyers (QIB) | 22,56,000 | 58.72% | 50% |
| QIB, excluding anchor | 9,06,000 | 23.58% | — |
| Anchor investors | 13,50,000 | 35.14% | — |
| Market maker | 2,70,000 | — | — |
Source: ProspectusUpdated
Subscription
Category-wise subscription is published by the exchanges while the issue is open. It appears here once the figures are added.
Valuation
FY 2024-25 (standalone)- EPS (basic)
- ₹9.6
- EPS (basic) (FY 2024-25 (consolidated))
- ₹14.04
- P/E (FY 2024-25 (standalone) at issue price)
- 15.10×
- P/E (FY 2024-25 (consolidated) at issue price)
- 10.33×
- RoNW
- 38.10%
- RoNW (FY 2024-25 (consolidated))
- 41.71%
- NAV per share (FY 2024-25 (standalone) at issue price)
- ₹21.32
- NAV per share (FY 2024-25 (consolidated) at issue price)
- ₹28.49
Source: ProspectusUpdated
Financials
Consolidated, restated · ₹ crore| Period ended | 31 Mar 2025FY 2024-25 | 31 Mar 2024FY 2023-24 | 31 Mar 2023FY 2022-23 |
|---|---|---|---|
| Revenue from operations | 76.99 | 46.43 | 35.91 |
| EBITDA | 25.65 | 9.09 | 3.58 |
| Profit after tax | 16.42 | 3.84 | 0.35 |
| Net worth | 37.87 | 10.59 | 8.69 |
| Total borrowing | 27.39 | 24.01 | 22.66 |
FY 2024-25 vs FY 2023-24: revenue +65.8%, profit after tax +327.0%.
Source: ProspectusUpdated
About the company
The company manufactures male condoms in a range of flavours, selling its main product under the COBRA brand. Its manufacturing plant in Noida, Uttar Pradesh, has an installed capacity the company reports at about 562 million condoms a year. The business was earlier run as a sole proprietorship by its promoter and was transferred to the company in 2024.
- Incorporated
- 2024
- Industry
- Healthcare Products
- Sector
- Healthcare and Pharma
- CIN
- U22193DL2024PLC428183
- Website
- anonditamedicare.com
Source: ProspectusUpdated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Mrs. Sonia Ghosh | — | — |
| Mr. Reshant Ghosh | — | — |
| Mr. Anupam Ghosh | 83.95% | 61.71% |
Source: ProspectusUpdated
Objects of the issue
₹ crore| Purpose | Amount |
|---|---|
| Capital expenditure for purchase of plant and machinery | 6.00 |
| Working capital requirements | 35.00 |
| Unidentified acquisition and general corporate purposes | 20.16 |
Source: ProspectusUpdated
Peer comparison
As listed in the offer document| Company | EPS | P/E | RoNW | NAV per share |
|---|---|---|---|---|
| Anondita Medicare LimitedIssuer | ₹9.6 | 15.10× | 38.10% | ₹21.32 |
| Cupid Limited | ₹1.52 | 110.38× | 11.96% | ₹12.75 |
Source: ProspectusUpdated
Strengths and risks
Our summary of what the offer document statesStrengths
- Manufactures condoms with a flagship brand and a range of flavours.
- Reports installed capacity of about 562 million condoms a year.
- Has a multi-year operating history in condom manufacturing through its predecessor business.
- Reported revenue and profit growth in FY 2024-25.
Risks
- A large share of revenue comes from a few customers, with top ten customers at about 99% of revenue in FY 2024-25.
- Significant revenue depends on government tenders that can lead to debarment or suspension.
- The company had negative operating or investing cash flows in some past periods.
- Promoter holds most of the pre-issue shares, so post-issue control stays concentrated.
- There has been no prior public market for the shares and the price may not be indicative after listing.
Source: ProspectusUpdated
Documents
Contacts
Source: ProspectusUpdated
Allotment status
Check whether shares were allotted on the official pages below, using your PAN, application number or DP/client ID. Results appear once the basis of allotment is finalised.
- Allotment
- Refunds
- Demat credit
- Listing
Source: ProspectusUpdated
After listing
Listing price, day-one high and low, and the change from the issue price (₹145) appear here after the shares list on NSE Emerge.
Work out the gain or loss on allotted shares after charges and tax →
Frequently asked questions
When does the Anondita Medicare IPO open and close?
According to the Prospectus, the issue opens on Friday, 22 August 2025 and closes on Tuesday, 26 August 2025. These dates are tentative.
What is the Anondita Medicare IPO price band?
The final issue price is ₹145 per share.
What is the lot size of the Anondita Medicare IPO?
One lot is 1,000 shares, which is ₹1.45 L at ₹145 per share.
Where will Anondita Medicare shares list?
On NSE Emerge. The tentative listing date is Monday, 1 September 2025.
Who is the registrar of the issue?
Maashitla Securities Private Limited (SEBI registration INR000004370). Allotment status is checked on the registrar's website.
How do I check the Anondita Medicare IPO allotment status?
The basis of allotment is expected to be finalised on Thursday, 28 August 2025. After that, search by PAN, application number or DP/client ID on the registrar's website (Maashitla Securities Private Limited). Shares that are allotted are credited to your demat account; for an application that is not allotted, the blocked amount is released.
How will the money raised be used?
₹6 Cr for capital expenditure for purchase of plant and machinery, ₹35 Cr for working capital requirements, ₹20.16 Cr for unidentified acquisition and general corporate purposes.
Related IPOs
More healthcare and pharma IPOs
- Paras Healthcare₹695Listed · 21 Oct – 23 Oct 2026
- Nephrocare Health Services₹438–460Listed · 10 Dec – 12 Dec 2025
- Park Medi World₹162Listed · 10 Dec – 12 Dec 2025
- CORONA Remedies₹1,062Listed · 8 Dec – 10 Dec 2025
Also managed by Narnolia Financial Services
All Narnolia Financial Services IPOs →Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.